| 中文名称 | 甘氨胆酸 |
| 英文名称 | Glycocholic acid |
| CAS号 | 475-31-0 |
| 分子式 | C26H43NO6 |
| 分子量 | 465.63 |
| EINECS号 | 207-494-9 |
| 熔点 | 128°C |
| 沸点 | 568.76°C (rough estimate) |
| 密度 | 1.1336 (rough estimate) |
| 折射率 | 1.6000 (estimate) |
| LogP | 1.650 |
| 溶解度 | 甲醇:0.1 g/mL,澄清,无色 |
| 形态 | 固体 |
| 酸度系数(pKa) | 4.4(at 25℃) |
| 颜色 | 白色至类白色 |
| 水溶解性 | 329.9mg/L(20 ºC) |
| 默克索引编号 | 13,4507 |
| 稳定性 | 吸湿性 |
| 危险品标志 | N |
| 危险类别码 | 51/53 |
| 安全说明 | 61 |
| 危险品运输编号 | UN 3077 9/PG 3 |
| WGK Germany | 3 |
|
Human Endogenous Metabolite
|
Glycocholic acid (GC) increases the cytotoxicity of epirubicin, significantly increases the intracellular accumulation of epirubicin in Caco-2 cells and the absorption of epirubicin in rat small intestine, and intensified epirubicin-induced apoptosis. Glycocholic acid and epirubicin significantly reduce mRNA expression levels of human intestinal MDR1, MDR-associated protein (MRP)1, and MRP2; downregulate the MDR1 promoter region; suppress the mRNA expression of Bcl-2; induce the mRNA expression of Bax; and significantly increase the Bax-to-Bcl-2 ratio and the mRNA levels of p53, caspase-9 and -3. A combination of anticancer drugs with Glycocholic acid can control MDR via a mechanism that involves modulating P-gp and MRPs as well as regulating apoptosis-related pathways.